Literature DB >> 33052482

Clinical, economic, and organizational impact of pharmacists' interventions in a cognitive-behavioral unit in France.

Teddy Novais1,2,3, Fanny Maldonado4, Maxime Grail4, Pierre Krolak-Salmon5,6,7, Christelle Mouchoux4,5,7.   

Abstract

Objective Evaluate the clinical, economic, and organizational impact of pharmaceutical interventions performed during medication review in a cognitive-behavioral unit. Setting Study conducted in a cognitive-behavioral unit with retrospective data from January 2011 to june 2017. Methods This study was conducted from retrospective data of medication review in a cognitive-behavioral unit. During medication review, pharmacists identified relevant drug related problems lead to a pharmaceutical intervention which is submitted to the physician. All pharmaceutical interventions carried out from January 2011 to june 2017 were retrospectively analyzed to evaluate their clinical, economic and organizational impact using a multidimensional tool. Main outcome measure CLinical, Economic and Organizational impact using the CLEO tool. Results During the study period, 543 drug related problems and pharmaceutical interventions were recorded for patients hospitalized in the cognitive-behavioral unit (79.0 ± 9.5 years, 59% female). The most common types of drug related problems identified were 'non conformity to guidelines / contra-indication' (28.7%), 'drug without indication' (21.7%), and 'improper administration' (15.1%). The majority of pharmaceutical interventions were considered to have at least a clinical significant impact from the pharmacist's perspective (74%). Regarding the economic and organizational dimensions, 55.2% of pharmaceutical interventions would decrease the costs of care and 35.9% of pharmaceutical interventions would be favorable on the quality of care process. Conclusions The present study shows that the pharmacist may detect a high number of drug related problems with significant clinical relevance during medication review in a cognitive-behavioral unit. Describing and identifying significant pharmaceutical interventions in cognitive-behavioral unit patients allow us to better understand and improve clinical practice in this population.

Entities:  

Keywords:  Alzheimer's disease and related dementia; Clinical relevance; Cognitive-behavioral units; Economic impact; France; Organizational impact; Pharmaceutical interventions

Year:  2020        PMID: 33052482     DOI: 10.1007/s11096-020-01172-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  2 in total

Review 1.  [Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].

Authors:  Teddy Novais; Christelle Mouchoux
Journal:  Geriatr Psychol Neuropsychiatr Vieil       Date:  2019-03-01

Review 2.  Potential drug-drug interactions in Alzheimer patients with behavioral symptoms.

Authors:  Giuseppe Pasqualetti; Sara Tognini; Valeria Calsolaro; Antonio Polini; Fabio Monzani
Journal:  Clin Interv Aging       Date:  2015-09-08       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.